This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

He was surprised to discover, for example, that a photo of the GSK headquarters building attracted more positive comments than a story about a community partnership. A recent example of content ...

Tom Lowe speaks to the practice's director about why the overlooked parts of public infrastructure deserve a fresh ...

GlaxoSmithKline Pharmaceuticals Limited ... towards renovation of its corporate office into a modern workplace. In September 2020, the Company launched tetravalent influenza flu vaccine, Fluarix ...

Under the patronage of H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, Abu Dhabi Global Healthcare Week 2025 will be held at ...

Stroke is the fourth leading cause of death among Hispanic men and the third leading cause for Hispanic women in the United States. Yet, according to CDC reports, only 58% of Hispanic adults can ...

In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic ... and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany ...

The vaccines studied, Zostavax and Shingrix, both appeared to offer protection. Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...